The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells

mAbs

Volumn 6, Issue 5, 2014, Pages 1211-1219

  Ram, Sripad ^a,b   Kim, Dongyoung ^a,b   Ober, Raimund J ^a,b   Ward, E Sally ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b The University of Texas at Dallas   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRANSFERRIN; TRASTUZUMAB;

ARTICLE; BREAST CANCER CELL LINE; CELL MEMBRANE; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; ENDOCYTOSIS; HUMAN; HUMAN CELL; INTERNALIZATION; MALE; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS;

EID: 84913537263     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29865     Document Type: Article

References (28)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/10.1126/science.3798106
2. Longva KE, Pedersen NM, Hasleka IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005; 116:359-67; PMID:15800944; http://dx.doi. org/10.1002/ijc.21015
3. Hommelgaard AM, LerdrupM, van Deurs B. Association with membrane protrusions makes ErbB2 an internaliza-tion-resistant receptor. Mol Biol Cell 2004; 15:1557-67; PMID:14742716; http://dx.doi.org/10.1091/mbc.E03-08-0596
4. Austin CD, De Mazi-ere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15:5268-82; PMID:15385631; http://dx.doi.org/10.1091/mbc.E04-07-0591
5. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71:2250-9; PMID:21406401; http://dx.doi.org/10.1158/0008-5472.CAN-10-2277
6. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61:4892-900; PMID:11406568
7. Henson ES, Hu X, Gibson SB. Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 2006; 12:845-53; PMID:16467098; http://dx.doi.org/ 10.1158/1078-0432.CCR-05-0754
8. Scaltriti M, Verma C, Guzman M, Jimenez J, Parra JL, Pedersen K, SmithDJ, Landolfi S, Ramon y, Cajal S,Arribas J, et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009; 28:803-14; PMID:19060928; http:// dx.doi.org/10.1038/onc.2008.432
9. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, et al. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 2006; 70:1534-41; PMID:16887935; http://dx.doi.org/10.1124/ mol.106.023911
10. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64:15-29; PMID:23043493; http://dx.doi.org/10.1146/annurev-med-050311-201823
11. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37; PMID:12204533; http://dx.doi.org/ 10.1016/S1535-6108(02)00097-1
12. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-Her-2/neu antibody in androgendependent and -independent human xenograft models. Cancer Res 1999; 59:4761-4;PMID:10519379
13. Arteaga CL. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors? J Clin Oncol 2006; 24:3722-5; PMID:16847283; http://dx. doi.org/10.1200/JCO.2006.06.5268
14. Potts SJ, Krueger JS, Landis ND, Eberhard DA, Young GD, Schmechel SC, Lange H. Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. Lab Invest 2012; 92:1342-57; PMID:22801299; http://dx.doi.org/10.1038/ labinvest.2012.91
15. Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Park SY. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 2012; 25:938-48; PMID:22388760; http://dx.doi. org/10.1038/modpathol.2012.36
16. Cho HS,Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392
17. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http:// dx.doi.org/10.1016/S1535-6108(04)00083-2
18. Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, LauffenburgerDA,Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 2010; 107:13252-7; PMID:20616078; http://dx.doi.org/10.1073/pnas.0913476107
19. OberRJ, MartinezC, Vaccaro C, Zhou J, Ward ES.Visualizing the site and dynamics of IgGsalvage by theMHCclass I-related receptor, FcRn. J Immunol 2004; 172:2021-9; PMID:14764666; http://dx.doi.org/10.4049/ jimmunol.172.4.2021
20. Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, Ober RJ. From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell 2005; 16:2028-38; PMID:15689494; http://dx.doi.org/ 10.1091/mbc.E04-08-0735
21. Gan Z, Ram S, Vaccaro C, Ober RJ, Ward ES. Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery. Traffic 2009; 10:600-14; PMID:19192244; http://dx.doi.org/ 10.1111/j.1600-0854.2009.00887.x
22. Prabhat P, Gan Z, Chao J, Ram S, Vaccaro C, Gibbons S, Ober RJ, Ward ES. Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy. Proc Natl Acad Sci U S A 2007; 104:5889-94; PMID:17384151; http://dx.doi.org/10.1073/pnas.0700337104
23. Piper RC, Katzmann DJ. Biogenesis and function of multivesicular bodies. Annu Rev Cell Dev Biol 2007; 23:519-47; PMID:17506697; http://dx.doi.org/ 10.1146/annurev.cellbio.23.090506.123319
24. Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M, Erbersdobler A, Eichelberg C, Fisch M, Brummendorf TH, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010; 16:1553-60; PMID:20179235; http://dx.doi.org/10.1158/1078-0432.CCR-09-2546
25. de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hers-berger-Gimenez V, et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J Clin Oncol 2007; 25:257-62; PMID:17235043; http://dx.doi.org/ 10.1200/JCO.2006.07.0888
26. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004; 60:332-7; PMID:15264245; http://dx.doi.org/10.1002/pros.20065
27. Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol Biol 1992; 224:487-99; PMID:1560463; http://dx.doi. org/10.1016/0022-2836(92)91010-M
28. Chao J,Ward ES, Ober RJ. A software framework for the analysis of complexmicroscopy image data. IEEE Trans Inf Technol Biomed 2010; 14:1075-87; PMID:20423810; http://dx.doi.org/10.1109/TITB.2010.2049024